60 Degrees Pharmaceuticals Inc
SXTP
View Detailed Chart
4.160USD
+0.310+8.05%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
4.27MMarket Cap
3.70P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+8.05%
5 Days
+0.24%
1 Month
+101.90%
6 Months
+209.29%
Year to Date
+104.60%
1 Year
+57.28%
View Detailed Chart
TradingKey Stock Score of 60 Degrees Pharmaceuticals Inc
Currency: USD Updated: 2026-02-06Key Insights
60 Degrees Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 101 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.60.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
60 Degrees Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
60 Degrees Pharmaceuticals Inc Highlights
StrengthsRisks
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 33.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 681.35K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 681.35K.
Overvalued
The company’s latest PE is 3.70, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.23K shares, decreasing 35.34% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 20.00 shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
17.600
Target Price
+357.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
60 Degrees Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
60 Degrees Pharmaceuticals Inc Info
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Ticker SymbolSXTP
Company60 Degrees Pharmaceuticals Inc
CEODow (Geoffrey S)
Websitehttps://60degreespharma.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69070.010
-900.120 (-1.29%)
282.580
+22.390 (+8.61%)
2057.630
+5.900 (+0.29%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
